Brain-Soultherapy s.r.o.
- Address
- K Nemocnici 1904, 272 01 Kladno, Czechia
Nervous System Diseases
At Brain-Soultherapy s.r.o. in Kladno, clinical research in neurology focuses on migraine and Alzheimer’s disease-related conditions. These studies are designed to assess new options for preventing headaches, easing agitation, and improving symptoms linked to brain disorders.
- Evaluating treatments for chronic and episodic migraine
- Studying therapies for agitation in Alzheimer’s disease dementia
- Assessing approaches for Alzheimer disease psychosis
The site’s work in this therapeutic area is centered on testing whether emerging therapies can offer better symptom control and longer-term safety for people living with neurological illness.
Psychiatry and Psychology
Clinical trials in psychiatry at this hospital/clinic examine major depressive disorder and related symptoms such as anhedonia. The research aims to improve how depression is treated when current antidepressants are not providing enough relief.
- Testing new therapies for major depressive disorder
- Exploring treatment options for MDD with moderate-to-severe anhedonia
- Evaluating the effectiveness and tolerability of longer-term depression treatments
These studies reflect a strong interest in finding better ways to reduce depressive symptoms and support patients who have not responded adequately to standard care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Brain-Soultherapy s.r.o.
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Multicenter, Randomized, Double blind, Placebo controlled Trial of the Safety and Efficacy of Flexible Doses of SEP 363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder. | Otsuka Pharmaceutical Development & Commercialization Inc. | Phase IV | Not Recruiting | Mar 2023 | Nov 2025 |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine | 2 | Unknown | 2024-07-18 | 2024-09-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.